{"id":"NCT00523341","sponsor":"Amgen","briefTitle":"Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis","officialTitle":"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08-07","primaryCompletion":"2015-07-19","completion":"2015-07-19","firstPosted":"2007-08-31","resultsPosted":"2016-07-12","lastUpdate":"2022-11-07"},"enrollment":4550,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteopenia","Osteoporosis"],"interventions":[{"type":"BIOLOGICAL","name":"Denosumab","otherNames":["AMG 162","Prolia"]}],"arms":[{"label":"Denosumab","type":"EXPERIMENTAL"}],"summary":"The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who previously received denosumab or placebo, respectively.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"84 months","effectByArm":[{"arm":"Placebo / Denosumab","deltaMin":2070,"sd":null},{"arm":"Denosumab / Denosumab","deltaMin":2173,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29105841","29672714","28546097","32058020","32092479","30244369","28277603","30759221","28449657","31201481","31125092","30919997","33211870","36088628","23979955","22113951"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":945,"n":2206},"commonTop":["Arthralgia","Back pain","Hypertension","Nasopharyngitis","Osteoarthritis"]}}